A small case series reports three neonatal epilepsy cases linked to vitamin B6 metabolism genes, reinforcing that early recognition and the right confirmatory testing can change outcomes. Pyridoxine-dependent epilepsy (PDE) is rare, but it is one of the most important “don’t-miss” causes of neonatal seizures because treatment can be effective. This report adds three more […]

Three “Vitamin B6-Dependent” Newborn Seizure Stories: Why the Gene (ALDH7A1 vs PNPO) Matters

When PDE Looks Like “Mitochondrial Disease”: A Case with Lactic Acidosis, Rhabdomyolysis, and Hyperammonemia

A report of PDE-ALDH7A1 shows how early metabolic lab abnormalities can mimic other disorders, and how targeted biomarkers can quickly point back to a treatable B6-pathway epilepsy.

The “Saccharopine Pathway” and a New Drug Target: Why LKR (AASS) Is on Researchers’ Radar for PDE

A review explains two lysine-breakdown routes in the body and argues that reducing flux through the saccharopine pathway could be therapeutic for PDE-ALDH7A1 and related disorders.

A case series summarizes seizure patterns, EEG changes, and ALDH7A1 variant findings in six children, emphasizing that early pyridoxine can normalize EEG and improve long-term outlook. Even within PDE-ALDH7A1, families can see very different seizure types and severity. This report reviews six children treated from 2017 to 2023, with most starting seizures in the neonatal […]

Six Chinese Children with PDE: What Their EEGs and Gene Variants Can Teach Us About Early Recognition

A Devastating Reminder: Refractory Neonatal Seizures, Hyperammonemia, and an ALDH7A1 Diagnosis

A neonatal case report describes multifocal seizures with severe metabolic instability and a confirmed ALDH7A1 pathogenic variant, stressing how urgent early recognition can be.

Newborn Screening for PDE: A High-Throughput Lab Workflow Using 2-OPP, Oxo-PIP, and Pipecolate

A methods-and-performance study supports adding PDE-ALDH7A1 to existing newborn screening systems by measuring 2-OPP and confirmatory markers in a single FIA-MS/MS assay.

A center cohort study tracks biochemical changes and practical adherence issues with lysine reduction therapies in 17 PDE-ALDH7A1 patients.

17 Patients, 15 Years of Practice: What a PDE Center Cohort Learned About Lysine-Restricted Diet (and Arginine)

Proof-of-Concept: Blocking LKR Upstream Can Prevent Toxic Metabolite Build-Up and Rescue Brain Function in a PDE Mouse Model

A mouse genetics study shows that disrupting lysine alpha-ketoglutarate reductase (LKR) upstream of ALDH7A1 can eliminate toxic intermediates and reverse seizures and cognitive deficits in an ALDH7A1-deficient model.

What’s the Evidence for “Triple Therapy” in PDE? A Systematic Review of B6, Lysine Restriction, and Arginine

A systematic review compares pyridoxine alone versus adding lysine-restricted diet and/or arginine, with a focus on seizure control and neurodevelopmental outcomes.

© 2023 Cure PDE Foundation | All Rights Reserved | Terms of Use | Privacy Policy | Site Credit